Conference|Interdisciplinary Prostate Cancer Congress and Other Genitourinary Malignancies Scott T. Tagawa, MD, MS, FACP, FASCO, highlights a key difference between oral androgen receptor inhibitor drugs and therapeutic radionuclides for the treatment of prostate cancer. This...
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299:289-295.D'Amico A.V., Chen M.H., Renshaw A.A., Loffredo M., Kantoff P.W. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA ...
The response of prostate cancer to radiation was well-documented in the pre-PSA era. Large palpable tumors resolved within months of treatment with relatively modest radiation doses of 64–70Gy. The use of PSA-based failure as an endpoint, however, has made it clear that cure rates were muc...
Pelvic radiation is a common therapy for the treatment of prostate cancer. A complication of this therapy, radiation proctitis, may be limited to the direct posttreatment period or it may appear as serious complications that occur months to years after therapy has been completed. Mucosal damage, ...
Biochemical failure after primary external beam radiotherapy for prostate cancer is common, and a significant proportion of these failures are due to local residual or recurrent disease. Early or delayed palliation using androgen deprivation therapy is the most common approach. Although a conservative ...
report reviews the utilization and subsequent retention of an endoscopic capsule in a symptomatic patient who had a previous small bowel resection caused by the sequelae of radiation therapy to the abdomen and pelvis for endometrial cancer... J Majeski - 《International Surgery》 被引量: 22发表: ...
The objective of this work was to assess the relative impact of radiobiological parameters and radiation dose escalation on Tumor Control Probability for prostate cancer patients treated with radiation. Radiobiological parameters included alpha/beta ratios, cell surviving fraction at 2 Gy (SF(2) and ...
Radiotherapy (RT) for prostate cancer (PC) has steadily evolved over the last decades, with improving biochemical disease-free survival. Recently population based research also revealed an association between overall survival and doses ≥ 75.6 Gray (Gy) in men with intermediate- and high-risk PC....
Recent selected developments of the molecular science of prostate cancer (PrCa) biology and radiation oncology are reviewed. We present potential targets for molecular integration treatment strategies with radiation therapy (RT), and highlight potential strategies for molecular treatment in combination with...
Three-dimensional conformal radiation therapy: evidence-based treatment of prostate cancer. J. Armstrong, "Three-dimensional conformal radiation therapy: Evi- dence-based treatment of prostate cancer," Radiotherapy Oncol., vol. 64, pp. 235-237... J Armstrong - 《Radiotherapy & Oncology》 被引量:...